Patrick C Lee,Michael T Schweizer,Rosa Nadal
Patrick C Lee
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effe...
Eric Deutsch,Antonin Levy,Laurence Zitvogel
Eric Deutsch
Low-dose intestinal irradiation challenges the long-standing view of the gut as a radiation-sensitive organ to avoid. Clinical and mechanistic data suggest that targeted exposure of the small intestine within a 1 to 3 Gy window can remodel ...
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study [0.03%]
CAR-T细胞治疗或其他全身抗肿瘤治疗后多发性骨髓瘤患者第二原发恶性肿瘤的发病风险:一项真实世界比较研究
Attaya Suvannasankha,Mengying Li,Omonefe Omofuma et al.
Attaya Suvannasankha et al.
Purpose: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma (MM) who received CAR T therapy versus other systemic anticancer therapies (SACTs). ...
The biology of hypomorphic TP53 variants and implications for clinical management [0.03%]
Hypomorphic TP53变异的生物学特性及其对临床治疗的启示
Renyta Moses,Jacquelyn Powers,Alison S Levine et al.
Renyta Moses et al.
In individuals with classic Li Fraumeni Syndrome (LFS) due to a loss of function pathogenic germline variant in TP53, loss of p53 tumor suppressive function leads to a high risk of childhood cancers such as sarcomas, adrenal cortical carcin...
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses [0.03%]
用于评估治疗反应的非小细胞肺癌(NSCLC)患者中携带KRAS Q61突变的分子和临床特征研究
Lea Ruge,Felix John,Malte Verheyen et al.
Lea Ruge et al.
Introduction: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for 1-7% of allKRAS mutations in non-small cell lung cancer (NSCLC). The prognostic value of this cohort and its response to differ...
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial [0.03%]
恩夫莫单抗(TQB2618)联合派普利单抗或化疗治疗复发/转移性鼻咽癌的多中心、两队列、Ⅱ期临床试验
Cheng Xu,Si-Yang Wang,Man Nie et al.
Cheng Xu et al.
Purpose: To evaluate the efficacy and safety of dual immunotherapy blocking T-cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) and programmed cell death protein-1 (PD-1) in recurrent/metastatic nasopharyn...
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial [0.03%]
brigimadlin与多柔比星治疗高级别去分化的脂肪肉瘤:来自Brightline-1随机II/III期临床试验的疗效、安全性及转化数据
Patrick Schöffski,Roberta Sanfilippo,Javier Martín-Broto et al.
Patrick Schöffski et al.
Purpose: The phase 2/3 Brightline-1 trial (NCT05218499) assessed the MDM2-p53 antagonist brigimadlin versus standard-of-care doxorubicin as first-line treatment for MDM2-amplified, locally advanced/metastatic dedifferenti...
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastoma [0.03%]
伊法布珠单抗在复发性胶质母细胞瘤患者中的I期和药代动力学研究
Hui K Gan,Lawrence Cher,Po-Ling Inglis et al.
Hui K Gan et al.
Purpose: To undertake a Phase 1 and Biodistribution study of the EphA3 antibody ifabotuzumab, and its zirconium labelled derivative 89Zr-ifabotuzumab, in glioblastoma patients. ...
Dihydropyrimidine dehydrogenase testing: From Pharmacogenomics to Equitable Practice [0.03%]
二氢嘧啶脱氢酶检测:从药物基因组学走向公平实践
Jacquelyne J Gaddy,Pamela L Kunz,Raghav Sundar
Jacquelyne J Gaddy
This commentary on a cohort study of patients with uncommon DPYD variants resulting in increased toxicities highlights the importance of expanding the current DPYD testing profile, the limitations of current testing, and the critical need t...
A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma [0.03%]
索托珠单抗联合仑伐替尼治疗晚期肝细胞癌患者的Ib/II期试验
Hong Jae Chon,Jeong Heo,Do Young Kim et al.
Hong Jae Chon et al.
Purpose: Immunotherapy has significantly improved outcomes in advanced hepatocellular carcinoma (HCC). However, most patients eventually progress, and second-line options remain limited. Fostrox, a liver targeted prodrug,...